CTXR — Citius Pharmaceuticals Cashflow Statement
0.000.00%
- $24.67m
- $22.08m
Annual cashflow statement for Citius Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.5 | -23.1 | -33.6 | -32.5 | -39.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.33 | 1.36 | 4.28 | 6.72 | 12.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.867 | -2.72 | 0.24 | -4.01 | -1.69 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -16.9 | -24.3 | -28.4 | -29.1 | -28.2 |
| Capital Expenditures | -0.002 | -40 | 0 | — | -5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 0 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.002 | -40 | 0 | 0 | -5 |
| Financing Cash Flow Items | — | 18.5 | 0 | — | -3.83 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 22.9 | 120 | 0 | 13.8 | 9.97 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.97 | 56.2 | -28.4 | -15.2 | -23.2 |